This application seeks renewal of a program that is now in its 35th year. The proposal comprises four scientific projects focused on studies of the mechanisms of hypoxic pulmonary hypertension (PH). The proposed studies are collectively founded on the hypothesis that the pathogenesis of hypoxic PH involves both functional (vasoconstriction and wall stiffening) and structural (vascular wall thickening) components, and that both components involve hypoxia-induced alterations in resident cell function as well as recruitment and interactions with inflammatory and/or progenitor cells. Projects 1, and 3 represent continuation and evolution of current program projects, while Projects 2 and 4 have been added to incorporate complementary new directions and expertise. The projects are highly interactive, both conceptually and in the performance and communication of experimental results, share numerous models and techniques, and are supported by three strong cores: administrative, animal, and tissue. The project leaders, Drs. Stenmark, Nemenoff, Klemm and Geraci have worked together on studies regarding cell signalling and of pulmonary hypertension for many years. The four projects address new and innovative hypotheses regarding the cellular mechanisms of chronic hypoxic PH. Project 1 explores the role of circulating myeloid mesenchymal progenitor cells, fibrocytes, in vascular remodeling and stiffening. Project 2 proposes that the phosphatase PTEN is a potent, endogenously produced inhibitor of SM proliferation and that SM-specific PTEN inactivation is an early and critical trigger driving vascular remodeling. Project 3 investigates how loss of CREB in SMC results in increases in SM proliferation, collagen elastin synthesis and VCAM-1 expression, which ultimately leads to accumulation of monocytes/progenitor cells and remodeling in the pulmonary arterial wall. Project 4 examines the role of disrupted PGI2 and PPAR? signaling in the aberrent cell growth characterizing chronic pulmonary vascular remodeling. These studies will provide new insights into the cellular/molecular mechanisms of chronic hypoxic pulmonary vasoconstriction and vascular stiffening and remodeling and may lead to novel, more effective therapy for hypoxic PH.

Public Health Relevance

Pulmonary hypertension (PH) complicates the clinical course of many chronic heart and lung diseases. Its'presence significantly increases the morbidity and mortality of the underlying disease. Current treatments are non-specific and often unsuccessful because mechanisms leading to the development of PH remain unclear. Our goal is to better understand the disease process, ultimately allowing for successful intervention.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
3P01HL014985-40S1
Application #
8914729
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Program Officer
Xiao, Lei
Project Start
1996-04-01
Project End
2015-06-30
Budget Start
2014-09-15
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ding, Yonghui; Xu, Xin; Sharma, Sadhana et al. (2018) Biomimetic soft fibrous hydrogels for contractile and pharmacologically responsive smooth muscle. Acta Biomater 74:121-130
Kumar, Rahul; Graham, Brian (2018) How does inflammation contribute to pulmonary hypertension? Eur Respir J 51:
Jiang, Xinguo; Nicolls, Mark R; Tian, Wen et al. (2018) Lymphatic Dysfunction, Leukotrienes, and Lymphedema. Annu Rev Physiol 80:49-70
Schäfer, Michal; Humphries, Stephen; Stenmark, Kurt R et al. (2018) 4D-flow cardiac magnetic resonance-derived vorticity is sensitive marker of left ventricular diastolic dysfunction in patients with mild-to-moderate chronic obstructive pulmonary disease. Eur Heart J Cardiovasc Imaging 19:415-424
D'Alessandro, Angelo; El Kasmi, Karim C; Plecitá-Hlavatá, Lydie et al. (2018) Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. Antioxid Redox Signal 28:230-250
Karoor, Vijaya; Fini, Mehdi A; Loomis, Zoe et al. (2018) Sustained Activation of Rho GTPases Promotes a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice. Arterioscler Thromb Vasc Biol 38:154-163
Stenmark, Kurt R; Graham, Brian B (2018) Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy? Cardiovasc Res 114:1057-1059
Madhavan, Krishna; Frid, Maria G; Hunter, Kendall et al. (2018) Development of an electrospun biomimetic polyurea scaffold suitable for vascular grafting. J Biomed Mater Res B Appl Biomater 106:278-290
Stenmark, Kurt R; Frid, Maria G; Graham, Brian B et al. (2018) Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension. Cardiovasc Res 114:551-564
Schäfer, Michal; Kheyfets, Vitaly O; Barker, Alex J et al. (2018) Reduced shear stress and associated aortic deformation in the thoracic aorta of patients with chronic obstructive pulmonary disease. J Vasc Surg 68:246-253

Showing the most recent 10 out of 148 publications